abstract |
The invention relates to a method for treating lupus erythematosus with epratuzumab, where the course of treatment is 12 weeks, where epratuzumab is administered in a fixed dose of 600 mg once a week 4 times in a cumulative dose of 2400 mg of epratuzumab, followed by a repetition of the course of treatment. Epratuzumab is administered intravenously, subcutaneously or intramuscularly. |